Abstract Introduction Oncology therapy development has accelerated worldwide, with approvals based on safety and efficacy. This study compares approval timelines in Brazil, the United States, and Europe from 2010 to 2021, highlighting regulatory differences and their impact on patient access. In Brazil, after Brazilian Health Regulatory Agency (Agência Nacional de...
ABSTRACT Carcinosarcomas were reclassified by World Health Organization as high-grade uterine carcinomas in 2014. Due to its rare histology, comprising only 5% of uterine carcinomas, there is a small representation of this tumor in studies that evaluate metastatic uterine carcinomas treatment. In 2022, the treatment of metastatic uterine carcinomas has...
ABSTRACT To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March 2021 and comprised 20 medical oncologists focus on gynecological oncology. The panel answered...
ABSTRACT Cancer is the main public health problem in Brazil and the world, and if the National Oncological Care Policy is not modified, cancer will become the leading cause of death in the country in 2029. However, the guidelines of the Ministry of Education do not have oncology as a...
ABSTRACT Background and Objective: Cancer is expected to be the leading cause of death in Brazil by 2030. This scenario demands that health professionals, especially physicians, should be able to implement primary prevention, early detection and cancer patient support. Despite this unquestionable need, there is a clear gap in Oncology training...
